Addressing the HIV epidemic in Eastern Europe and Central AsiaWorking in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021 Share XAddressing the HIV epidemic in Eastern Europe and Central Asiahttps://pharmaphorum.com/patients/gilead-hiv-epidemic-eastern-europe-central-asia/
Improving access to treatments in challenging marketsThe COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at Share XImproving access to treatments in challenging marketshttps://pharmaphorum.com/patients/gilead-jirair-ratevosian-treatment-access/
New Cell & Gene Therapy Collective seeks to boost UK adoptionThe UK has been a global leader in introducing cell and gene therapies that can potentially transform the Share XNew Cell & Gene Therapy Collective seeks to boost UK adoptionhttps://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyIn 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the Share XAllogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapyhttps://pharmaphorum.com/news/allogene-announces-pivotal-trial/
Collaboration is key to advancing cell therapy researchDr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company Share XCollaboration is key to advancing cell therapy researchhttps://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/
Gilead’s Trodelvy approved in metastatic urothelial cancerGilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Share XGilead’s Trodelvy approved in metastatic urothelial cancerhttps://pharmaphorum.com/news/gileads-trodelvy-approved-in-metastatic-urothelial-cancer/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
Gilead pushes on with NASH partnership with Novo NordiskGilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – Share XGilead pushes on with NASH partnership with Novo Nordiskhttps://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/
Lymphoma Action – championing the patient voice in cell therapyLymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill Share XLymphoma Action – championing the patient voice in cell therapyhttps://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/
